Trial Profile

Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 May 2020 Results evaluating PK and safety profiles of single dose CVT-301 administered with oral carbidopa (CD) and oral CD/LD in patients with Parkinson's disease in the fed state, published in the Clinical Therapeutics
01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
12 Feb 2020 According to an Acorda Therapeutics media release, data from this trial will be presented at the upcoming 3rd Pan American Parkinson's Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com